BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 10643174)

  • 1. The multisystem adverse effects of NSAID therapy.
    James DS
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S1-7. PubMed ID: 10643174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Gastrointestinal side effects of non-steroidal anti-inflammatory drugs in high-risk patients--role of selective cyclooxygenase inhibitors].
    PrĂ³nai L
    Orv Hetil; 2001 Sep; 142(35):1899-905. PubMed ID: 11601177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.
    Tindall E
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S13-7. PubMed ID: 10643176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From prostaglandin replacement to specific COX-2 inhibition: a critical appraisal.
    Kremer J
    J Rheumatol Suppl; 2000 Oct; 60():9-12. PubMed ID: 11032096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors: indications and complications.
    Pascucci RA
    J Am Osteopath Assoc; 2002 Sep; 102(9):487-9. PubMed ID: 12361181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Helicobacter pylori infection and the use of NSAIDs.
    Bazzoli F; De Luca L; Graham DY
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):775-85. PubMed ID: 11566040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
    Laine L
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multisystem adverse effects of NSAID therapy.
    James DS
    J Am Osteopath Assoc; 1999 Nov; 99(11_suppl):S1-S7. PubMed ID: 26981697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COX-2 inhibitors. What is their place?
    McGettigan P
    Aust Fam Physician; 2000 Sep; 29(9):847-52. PubMed ID: 11008387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inadequate prevention of NSAID-induced gastrointestinal events.
    Herings RM; Goettsch WG
    Ann Pharmacother; 2004 May; 38(5):760-3. PubMed ID: 15031416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scientific rationale for specific inhibition of COX-2.
    Bolten WW
    J Rheumatol Suppl; 1998 May; 51():2-7. PubMed ID: 9596548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis.
    Ofman JJ; Badamgarav E; Henning JM; Knight K; Laine L
    Am J Med; 2004 Jun; 116(12):835-42. PubMed ID: 15178499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COX-2-specific inhibition: implications for clinical practice.
    Pascucci RA
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S18-22. PubMed ID: 10643177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonsteroidal anti-inflammatory drug gastropathy at the new millennium: mechanisms and prevention.
    Rich M; Scheiman JM
    Semin Arthritis Rheum; 2000 Dec; 30(3):167-79. PubMed ID: 11124281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of NSAID-induced gastroduodenal mucosal injury.
    Wallace JL
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):691-703. PubMed ID: 11566035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Are COX-2 inhibitors truly able to prevent NSAIDs-associated ulcer?].
    Nishida T; Tsujii M; Tsuji S
    Nihon Rinsho; 2004 Mar; 62(3):561-5. PubMed ID: 15038104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New NSAIDs and gastroduodenal damage.
    Folco GC
    Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():28-9. PubMed ID: 9032579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of NSAID-related gastroduodenal mucosal injury.
    Aalykke C; Lauritsen K
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):705-22. PubMed ID: 11566036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios].
    Limmer S; Ittel TH; Wietholtz H
    Z Gastroenterol; 2003 Aug; 41(8):719-28. PubMed ID: 12910426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.